- Home
- BCDA vs SYRA Comparison
BCDA vs SYRA Comparison
Compare BCDA & SYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- SYRA
- Stock Information
- Founded
- BCDA N/A
- SYRA 2020
- Country
- BCDA United States
- SYRA United States
- Employees
- BCDA N/A
- SYRA N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- SYRA Other Specialty Stores
- Sector
- BCDA Health Care
- SYRA Industrials
- Exchange
- BCDA Nasdaq
- SYRA Nasdaq
- Market Cap
- BCDA 7.9M
- SYRA 7.8M
- IPO Year
- BCDA N/A
- SYRA 2023
- Fundamental
- Price
- BCDA $2.68
- SYRA $0.46
- Analyst Decision
- BCDA Strong Buy
- SYRA
- Analyst Count
- BCDA 1
- SYRA 0
- Target Price
- BCDA $25.00
- SYRA N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- SYRA 117.4K
- Earning Date
- BCDA 11-06-2024
- SYRA 11-12-2024
- Dividend Yield
- BCDA N/A
- SYRA N/A
- EPS Growth
- BCDA N/A
- SYRA N/A
- EPS
- BCDA N/A
- SYRA N/A
- Revenue
- BCDA $428,000.00
- SYRA $7,069,566.00
- Revenue This Year
- BCDA $6.92
- SYRA $42.88
- Revenue Next Year
- BCDA N/A
- SYRA N/A
- P/E Ratio
- BCDA N/A
- SYRA N/A
- Revenue Growth
- BCDA 0.71
- SYRA 25.18
- 52 Week Low
- BCDA $1.96
- SYRA $0.34
- 52 Week High
- BCDA $23.25
- SYRA $8.37
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- SYRA 45.55
- Support Level
- BCDA $2.39
- SYRA $0.35
- Resistance Level
- BCDA $2.90
- SYRA $0.42
- Average True Range (ATR)
- BCDA 0.18
- SYRA 0.03
- MACD
- BCDA -0.00
- SYRA 0.03
- Stochastic Oscillator
- BCDA 53.70
- SYRA 99.82
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About SYRA Syra Health Corp.
Syra Health Corp is a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. The company leverages deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. It strives to offer comprehensive end-to-end solutions in health education services, population health management, behavioral and mental health, healthcare workforce and digital health.